Genetic and Epigenetic Alterations in Bladder Cancer

키워드

참고문헌 (99)

1. "Cancer facts & figures 2016" (2016)[URL]
2. "Surveillance, Epidemiology, and End Results" (2016)[URL]
3. Freedman ND, "Association between smoking and risk of bladder cancer among men and women", JAMA, 306, pp.737~745 (2011)
4. Brandau S, "Bladder cancer. I. Molecular and genetic basis of carcinogenesis", Eur Urol, 39, pp.491~497 (2001)
5. Feng Z, "4-aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene", Carcinogenesis, 23, pp.1721~1727 (2002)
6. Kaufman DS, "Bladder cancer", Lancet, 374, pp.239~249 (2009)
7. Prasad SM, "Urothelial carcinoma of the bladder: definition, treatment and future efforts", Nat Rev Urol, 8, pp.631~642 (2011)
8. Marko Babjuk, "EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016", European Urology (2016), Elsevier BV[DOI]
9. Morgan TM, "Bladder cancer", Curr Opin Oncol, 23, pp.275~282 (2011)
10. Gupta NP, "Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder", Urology, 73, pp.592~596 (2009)
11. Irani J, "BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder", Eur Urol, 35, pp.89~92 (1999)
12. Têtu B, "ImmunoCyt", uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma, 2005, pp.18, 83~89
13. van Rhijn BW, "Urine markers for bladder cancer surveillance: a systematic review", Eur Urol, 47, pp.736~748 (2005)
14. Mowatt G, "Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer", Health Technol Assess, 14, pp.331~ (2010)
15. Vineis P, "Models of carcinogenesis: an overview", Carcinogenesis, 31, pp.1703~1709 (2010)
16. Weinberg RA, "The biology of cancer" (2007), Garland Science
17. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of urothelial bladder carcinoma", Nature, 507, pp.315~322 (2014)
18. Gui Y, "Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder", Nat Genet, 43, pp.875~878 (2011)
19. Hedegaard J, "Comprehensive transcriptional analysis of early-stage urothelial carcinoma", Cancer Cell, 30, pp.27~42 (2016)
20. Soussi T, "Assessing TP53 status in human tumours to evaluate clinical outcome", Nat Rev Cancer, 1, pp.233~240 (2001)
21. Bakkar AA, "FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder", Cancer Res, 63, pp.8108~8112 (2003)
22. Wallerand H, "Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens", Carcinogenesis, 26, pp.177~184 (2005)
23. Robertson KD, "DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters", Nat Genet, 25, pp.338~342 (2000)
24. Korenjak M, "E2F-Rb complexes regulating transcription of genes important for differentiation and development", Curr Opin Genet Dev, 15, pp.520~527 (2005)
25. Dulić V, "p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest", Cell, 76, pp.1013~1023 (1994)
26. De Luca A, "A unique domain of pRb2", p130 acts as an inhibitor of Cdk2 kinase activity, 1997, pp.272, 20971~20974
27. Cappellen D, "Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas", Nat Genet, 23, pp.18~20 (1999)
28. di Martino E, "Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner", Oncogene, 28, pp.4306~4316 (2009)
29. Jebar AH, "FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma", Oncogene, 24, pp.5218~5225 (2005)
30. Williams SV, "Oncogenic FGFR3 gene fusions in bladder cancer", Hum Mol Genet, 22, pp.795~803 (2013)
31. Knowles MA, "Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer", Cancer Metastasis Rev, 28, pp.305~316 (2009)
32. Tamaskovic R, "Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K", AKT via RASp110crosstalk, 2016, pp.7, 11672~
33. Ghezraoui H, "Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining", Mol Cell, 55, pp.829~842 (2014)
34. Shtivelman E, "Fused transcript of abl and bcr genes in chronic myelogenous leukaemia", Nature, 315, pp.550~554 (1985)
35. Mayr C, "Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation", Science, 315, pp.1576~1579 (2007)
36. Balbás-Martínez C, "Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy", Nat Genet, 45, pp.1464~1469 (2013)
37. Morrison CD, "Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer", Proc Natl Acad Sci U S A, 111, pp.E672~E681 (2014)
38. Hartmann A, "Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder", Cancer Res, 62, pp.809~818 (2002)
39. Simoneau M, "Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest", Oncogene, 19, pp.6317~6323 (2000)
40. Weber RG, "Frequent loss of chromosome 9, homozygous CDKN2A", p14(ARF), Oncogene, pp.2007, 26[DOI]
41. Veltman JA, "Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors", Cancer Res, 63, pp.2872~2880 (2003)
42. Sharma S, "Epigenetics in cancer", Carcinogenesis, 31, pp.27~36 (2010)
43. Shen H, "Interplay between the cancer genome and epigenome", Cell, 153, pp.38~55 (2013)
44. Han H, "Epigenetic alterations in bladder cancer and their potential clinical implications", Adv Urol, 2012, pp.546917~ (2012)
45. Reinert T, "Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer", Adv Urol, 2012, pp.503271~ (2012)
46. Jones PA, "Rethinking how DNA methylation patterns are maintained", Nat Rev Genet, 10, pp.805~811 (2009)
47. Kulis M, "Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia", Nat Genet, 44, pp.1236~1242 (2012)
48. Yang X, "Gene body methylation can alter gene expression and is a therapeutic target in cancer", Cancer Cell, 26, pp.577~590 (2014)
49. Duymich CE, "DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells", Nat Commun, 7, pp.11453~ (2016)
50. Chen T, "Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells", Nat Genet, 39, pp.391~396 (2007)
51. Liang G, "Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements", Mol Cell Biol, 22, pp.480~491 (2002)
52. Jones PA, "The fundamental role of epigenetic events in cancer", Nat Rev Genet, 3, pp.415~428 (2002)
53. Reinert T, "Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers", Clin Cancer Res, 17, pp.5582~5592 (2011)
54. Wolff EM, "Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue", Cancer Res, 70, pp.8169~8178 (2010)
55. Wolff EM, "Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer", PLoS Genet, 6, pp.1000917~ (2010)
56. Chung W, "Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments", Cancer Epidemiol Biomarkers Prev, 20, pp.1483~1491 (2011)
57. Kandimalla R, "DNA methylationbased biomarkers in bladder cancer", Nat Rev Urol, 10, pp.327~335 (2013)
58. Costa VL, "Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples", Clin Cancer Res, 16, pp.5842~5851 (2010)
59. Kandimalla R, "Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers", Eur Urol, 61, pp.1245~1256 (2012)
60. Agundez M, "Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours", Eur Urol, 60, pp.131~140 (2011)
61. Rideout WM 3rd, "Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation", Mol Cell Biol, 14, pp.6143~6152 (1994)
62. Yamamoto E, "LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis", Cancer Epidemiol Biomarkers Prev, 17, pp.2555~2564 (2008)
63. Yu J, "A novel set of DNA methylation markers in urine sediments for sensitive", specific detection of bladder cancer, 2007, pp.13, 7296~7304
64. Yeh CM, "Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma", Oncotarget, 6, pp.29555~29572 (2015)
65. Renard I, "Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples", Eur Urol, 58, pp.96~104 (2010)
66. Friedrich MG, "Detection of methylated apoptosisassociated genes in urine sediments of bladder cancer patients", Clin Cancer Res, 10, pp.7457~7465 (2004)
67. Su SF, "A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence", Clin Cancer Res, 20, pp.1978~1989 (2014)
68. Kim J, "Invasive bladder cancer: genomic insights and therapeutic promise", Clin Cancer Res, 21, pp.4514~4524 (2015)
69. Kim EJ, "Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor", J Urol, 180, pp.1141~1145 (2008)
70. Maruyama R, "Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features", Cancer Res, 61, pp.8659~8663 (2001)
71. Marsit CJ, "Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer", Cancer Res, 65, pp.7081~7085 (2005)
72. Catto JW, "Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma", J Clin Oncol, 23, pp.2903~2910 (2005)
73. He YF, "Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA", Science, 333, pp.1303~1307 (2011)
74. Kohli RM, "TET enzymes, TDG and the dynamics of DNA demethylation", Nature, 502, pp.472~479 (2013)
75. Jones PA, "The epigenomics of cancer", Cell, 128, pp.683~692 (2007)
76. Munari E, "Global 5-hydroxymethylcytosine levels are profoundly reduced in multiple genitourinary malignancies", PLoS One, 11, pp.e0146302~ (2016)
77. Liu M, "Vitamin C increases viral mimicry induced by 5-aza-2’-deoxycytidine", Proc Natl Acad Sci U S A, 113, pp.10238~10244 (2016)
78. Jenuwein T, "Translating the histone code", Science, 293, pp.1074~1080 (2001)
79. Kouzarides T, "Chromatin modifications and their function", Cell, 128, pp.693~705 (2007)
80. Vallot C, "A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression", J Natl Cancer Inst, 103, pp.47~60 (2011)
81. Ellinger J, "Alterations of global histone H3K9 and H3K27methylation levels in bladder cancer", Urol Int, 93, pp.113~118 (2014)
82. Wu S, "Novel variants in MLL confer to bladder cancer recurrence identified by wholeexome sequencing", Oncotarget, 7, pp.2629~2645 (2016)
83. Charlet J, "Bivalent regions of cytosine methylation and H3K27 acetylation suggest an active role for DNA methylation at enhancers", Mol Cell, 62, pp.422~431 (2016)
84. Yoshino H, "Aberrant expression of microRNAs in bladder cancer", Nat Rev Urol, 10, pp.396~404 (2013)
85. Friedman JM, "The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2", Cancer Res, 69, pp.2623~2629 (2009)
86. Saito Y, "Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells", Cancer Cell, 9, pp.435~443 (2006)
87. Saito Y, "Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review", Clin Rev Allergy Immunol, 47, pp.128~135 (2014)
88. Cheng Y, "Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis", Onco Targets Ther, 8, pp.2089~2096 (2015)
89. Lorch Y, "Nucleosomes inhibit the initiation of transcription but allow chain elongation with the displacement of histones", Cell, 49, pp.203~210 (1987)
90. Lee CK, "Evidence for nucleosome depletion at active regulatory regions genome-wide", Nat Genet, 36, pp.900~905 (2004)
91. Lay FD, "The role of DNA methylation in directing the functional organization of the cancer epigenome", Genome Res, 25, pp.467~477 (2015)
92. Ghosh M, "Targeted therapies in urothelial carcinoma", Curr Opin Oncol, 26, pp.305~320 (2014)
93. Mooso BA, "The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence", J Urol, 193, pp.19~29 (2015)
94. You JS, "Cancer genetics and epigenetics: two sides of the same coin?", Cancer Cell, 22, pp.9~20 (2012)
95. Nervi C, "Epigenetic treatment of solid tumours: a review of clinical trials", Clin Epigenetics, 7, pp.127~ (2015)
96. Ding XL, "Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2’-deoxycytidine", Sci Rep, 6, pp.24545~ (2016)
97. Nebbioso A, "Trials with ‘epigenetic’drugs: an update", Mol Oncol, 6, pp.657~682 (2012)
98. Hurst CD, "Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis", Clin Cancer Res, 18, pp.5865~5877 (2012)
99. Mayland CR, "Vitamin C deficiency in cancer patients", Palliat Med, 19, pp.17~20 (2005)

관련 논문AI추천